Participated · Equity · Jun 2026

Omni develops a range of plant-based, vet-formulated dog foods, treats, supplements, dental sticks, shampoos and calming products using novel proteins from yeast, algae and pulses. The company sells dry foods and wet-style meals, training treats, and a portfolio of supplements addressing skin, breath, gut health and weight management. Omni is commercial and growing quickly—founders Guy Sandelowsky and Shiv Sivakumar say annualised sales rose from about £1M to close to £13M and the brand has helped more than 300,000 dogs, with a 130% sales lift and 20,000 new customers after its Dragons’ Den appearance. It is developing LeanPaws, an Ozempic-style weight-loss supplement for dogs; a placebo-controlled trial reported 77% of overweight dogs taking LeanPaws lost some weight, 63% reduced body fat composition, and 42% showed fewer begging behaviors with virtually no side effects. Omni highlights the lower carbon footprint of its recipes—about 73% fewer emissions than standard meat-based dog food—and cites avoided customer CO2e contributions over time. The company plans to use new funding to scale UK retail presence, enter the US market, continue clinical research, and expand the team.

Participated · Series A · Jun 2026

Neion Bio’s core product is the Raptor™ platform, which leverages genetic engineering to restrict recombinant protein production to chicken eggs as a means to manufacture complex, glycosylated biologic proteins. Founded in 2024, the company is positioning the platform to address scalability, resiliency, capital efficiency, speed, and the ability to express difficult-to-manufacture molecules. Neion plans to expand its pipeline across biosimilars, innovative medicines, critical reagents, and animal health and to commercialize via partnerships, including a recently announced multi-product biosimilars co-development and supply agreement with a major pharmaceutical company. The company is advancing proprietary technologies intended to enable production at meaningful scale within days and to shorten iteration cycles for molecule screening and production. Financially, Neion completed an oversubscribed $23 million Series A to fund these platform and pipeline initiatives.

Led · Seed · May 2026

Travv offers an AI-native, cloud-based diagnostic platform for veterinary medicine that integrates RIS, PACS, and LIS capabilities into a single system. The platform supports a growing suite of traditional and emerging diagnostic services for veterinary hospitals and providers. Led by founder and CEO Derick Whitley, DVM, DACVP, the company is headquartered in Stillwater, OK. Travv closed a $1.6M seed round to fund continued product development, hospital onboarding, commercial growth, and key integrations. The financing was led by Digitalis Ventures with participation from AniVC. No revenue, user metrics, prior funding rounds, or valuation were disclosed in the announcement.

Led · Series B · Mar 2026

Clasp applies a military-inspired ROTC model to healthcare by enabling employers to commit to clinicians before graduation and repay student loans over time in exchange for tenure. Its Loan-Linked Hiring approach replaces transactional sign-on bonuses with retention-based student loan repayment that vests with tenure; Clasp reports retention rates 2.5x higher than traditional hiring models. Across its network, employers have committed more than $130M in student loan repayment across thousands of programs, and customers include Boston Children’s Hospital, Memorial Sloan Kettering, MyEyeDr., Northwestern Medicine, Novant Health, OhioHealth, VCA Animal Hospitals, and others. The company plans to use the Series B proceeds to expand across health systems nationwide, deepen university partnerships, and scale the infrastructure that connects employers, schools, students, and financial institutions. Clasp was founded by Tess Michaels in 2018 and is based in Boston. The company positions student loan repayment as workforce infrastructure to reduce clinician turnover and support longer tenures.

Participated · Series B · Jan 2026

EpiBiologics is a San Mateo–based biotechnology company pioneering the degradation of disease-driving extracellular membrane and soluble proteins via its proprietary EpiTAC bispecific antibody platform. The company’s lead candidate, EPI-326, is designed to degrade all oncogenic forms of EGFR in a tumor-selective manner, aiming to overcome safety and resistance limitations of current EGFR therapies. Preclinical data show strong, durable efficacy with favorable safety and pharmacokinetic profiles, supporting both monotherapy and combination use across multiple cancer types. EpiBiologics plans to commence a first-in-human trial of EPI-326 in early 2026 for non-small cell lung cancer and head and neck squamous cell carcinoma. Proceeds from its recent financing will also expand a broader pipeline in oncology and immunology while bolstering internal capabilities. The company recently strengthened its leadership team by hiring Eric Humke, M.D., Ph.D., as Chief Medical Officer and Aaron Mishel as Chief Financial Officer, and added several industry leaders to its Board.